肝炎B治療の世界市場

肝炎B治療の世界市場は2030年までに54億米ドルに到達

2024年に47億米ドルと推定される肝炎B治療の世界市場は、2024年から2030年にかけてCAGR 2.3％で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである急性型は、CAGR 1.7%を記録し、分析期間終了時には35億米ドルに達すると予測されます。慢性型セグメントの成長率は、分析期間でCAGR 3.5％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 4.4％で成長予測

米国の肝炎B治療市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに10億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9％と1.7％と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の肝炎B治療市場- 主要動向と促進要因のまとめ

B型肝炎治療は機能的治癒と長期抑制の新時代へ？

B型肝炎の治療は、進歩する科学的調査、治療選択肢の改善、ウイルスの複雑なライフサイクルの深い理解によって、極めて重要な変革期を迎えています。従来、生涯にわたる抗ウイルス療法によって管理されてきた肝炎B治療は、肝硬変、肝細胞がん（HCC）、肝不全のリスクを低減するために、ウイルス複製を抑制することに重点を置いてきました。エンテカビル、テノホビルジソプロキシルフマル酸塩（TDF）、テノホビルアラフェナミド（TAF）を含むヌクレオシド（t）イド類似体などの第一選択薬は、持続的なウイルス抑制には有効であることが証明されているが、完全な治癒には至っていないです。しかし、新たな研究の波は、専門家が「機能的治癒」と呼ぶ、治療を継続しなくてもB型肝炎表面抗原（HBsAg）が消失し、HBV DNAが検出されないことを定義とする治癒を目指しています。カプシド集合体モジュレーター、siRNA阻害剤、免疫チェックポイントモジュレーターなど、臨床試験中の新規治療薬候補は、HBVのライフサイクルのさまざまな段階と宿主の免疫反応を標的としており、治療の限界を抑制の域を超えて押し上げようとしています。治療用ワクチンやT細胞活性化剤を含む免疫療法戦略もまた、持続的なウイルス貯蔵庫に対する身体の免疫反応を再び呼び起こすことを目的として、支持を集めています。抗ウイルス薬と免疫調節薬の併用療法は、治療後の持続的なコントロールに向けた前進として評価されています。これらの治験治療が臨床試験を経て進展するにつれ、治療のパラダイムは生涯管理から機能的治癒を目指す期間限定レジメンへと移行しつつあり、これはB型慢性肝炎に対する世界のアプローチにおける画期的な変化となるであろう。

公衆衛生のインフラとスクリーニングは、治療へのアクセスや受診を促進しているか？

B型肝炎に対する認識が高まるにつれ、公衆衛生のインフラや世界のスクリーニングの取り組みが改善され、治療へのアクセスや受診率に大きな影響を与えています。慢性HBV感染者の多くは、肝疾患のような合併症が生じるまで、自分の状態に気づいていません。これに対し、各国は国のスクリーニング・プログラムを拡大し、HBV検査を日常的な妊婦健診、献血者スクリーニング、一般健康診断に組み込んでいます。このような対策により、早期診断が可能になりつつあり、早期患者は抗ウイルス療法に良好に反応するため、これは極めて重要です。さらに、特にアジアやサハラ以南のアフリカなど、感染リスクの高い地域では、分散型ヘルスケアモデルや地域密着型のアウトリーチが導入され、十分な治療を受けられない人々の治療へのアクセスが改善されています。また、多くの国がWHOの勧告に沿って治療ガイドラインを改訂し、治療開始の障壁を減らし、抗ウイルス治療の適格基準を拡大しています。さらに、HBV管理をHIV/AIDS、結核、妊産婦の健康プログラムなど、より広範な保健サービスに統合することで、ケアの提供を合理化し、患者の転帰を改善しています。Gavi、世界基金、UNITAIDのような世界のドナーや組織は、薬剤費の助成や研究所のインフラ構築を通じて、低・中所得国を支援しています。一方、デジタルヘルスプラットフォームや遠隔医療サービスは、遠隔地や農村部でのアウトリーチを拡大し、バーチャル診察、遠隔モニタリング、デジタル処方管理を可能にしています。このような取り組みにより、HBV治療は、診断から治療継続までのカスケードが改善され、よりアクセスしやすく、手頃な価格で、世界中の多様な患者集団のニーズに合った治療が受けられるようになっています。

進化する患者人口統計と併存疾患は、治療戦略をどのように再構築しているのか？

HIV、D型肝炎、糖尿病、非アルコール性脂肪性肝疾患（NAFLD）などの併存疾患の増加とともに、患者の人口統計が変化していることが、肝炎B治療戦略に複雑さを加えています。高齢者における慢性疾患の増加は、HBV治療を開始する際に、薬剤の選択が腎臓や骨に関連する合併症を悪化させないように、より総合的なアプローチをとることを臨床医に促しています。これは特に高齢者や腎臓に基礎疾患のある人に関連し、テノホビルアラフェナミド（TAF）は安全性プロファイルが改善されているため、TDFよりも好まれることが多いです。HIVとの同時感染は、薬物-薬物相互作用を回避し、両方のウイルスを確実に抑制するために治療レジメンを調和させなければならないため、別の臨床課題を提示します。D型肝炎ウイルス（HDV）に重複感染している患者（急速な疾患進行のリスクが高いグループ）に対しては、二重感染を効果的に管理するために、ブレビルチドのような新規の侵入阻害剤の使用を含む特殊な抗ウイルス戦略が検討されています。これと並行して、メタボリックシンドロームや肥満に関連した肝障害の世界の増加は、HBV患者における肝疾患の進行がもはやウイルス複製のみによるものではないため、治療タイミングやモニタリングプロトコールに影響を及ぼしています。線維化スコア、肝酵素動向、代謝指標を統合した新しいアルゴリズムは、医療提供者がリスクを層別化し、治療計画を個別化するのに役立っています。さらに、患者の服薬アドヒアランスとQOLへの配慮が治療設計の中心になりつつあり、1日1回投与の経口レジメンの開発や長時間作用型注射製剤の研究が進められています。このように、HBV患者プロファイルの多様化は、慢性肝炎治療における個別化医療のあり方を再定義し、より微妙で患者中心の治療経路を必要としています。

肝炎B治療セグメントの成長を加速させる市場および政策促進要因は何か？

肝炎B治療市場の成長は、疫学的動向、医薬品イノベーション、医療政策の進化、患者行動と結びついたいくつかの相互関連的な力によって牽引されています。世界全体では、2億5,000万人以上の人々が慢性HBVに罹患しており、その大多数が中低所得国に居住しています。この地域は現在、WHOの肝炎撲滅アジェンダの一環として、治療アクセスを積極的に拡大しています。治療ガイドラインが拡大され、より早期の肝疾患や線維化があまり進行していない患者も治療対象に含まれるようになったことで、治療対象者が拡大し、抗ウイルス療法への需要が高まっています。機能的治癒の実現、アドヒアランスの改善、長期毒性の軽減などを目指して開発中の次世代治療薬がいくつかあり、医薬品の技術革新が市場の勢いを増しています。同時に、ジェネリック医薬品の利用可能性が高まることで、特に患者負担の大きい国々では、第一選択抗ウイルス薬がより安価に入手できるようになり、患者数の増加や公衆衛生イニシアチブの拡大につながっています。各国政府や保健機関はB型肝炎撲滅計画に着手しており、治療補助金の予算配分、集中調達戦略、必須医薬品リストへの抗ウイルス薬の追加など、これらすべてが市場拡大に寄与しています。患者の行動も変化しており、健康意識の高まり、デジタルへの関与、病気の非体質化により、検査や早期介入を求める人が増えています。一方、製薬会社、NGO、保健省間のパートナーシップは、ラストワンマイル・デリバリーを改善するため、地域の治療ハブやサプライチェーンネットワークの確立に役立っています。モバイルベースのアドヒアランス・ツール、遠隔モニタリング・プラットフォーム、AIを活用した臨床判断支援システムなど、デジタルヘルス技術の採用は、患者の定着率とケアの質を高めています。これらの複合的な要因が肝炎B治療市場を前進させており、世界が最も蔓延している感染症の撲滅に近づく中で、長期的な力強い成長が見込まれています。

セグメント

タイプ（急性型、慢性型）;治療（免疫調整薬治療、抗ウイルス薬治療、ワクチン治療、手術治療）;流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

• AbbVie Inc.
• Alnylam Pharmaceuticals
• Altimmune Inc.
• Antios Therapeutics
• Arbutus Biopharma Corporation
• Assembly Biosciences
• Bristol-Myers Squibb
• Dicerna Pharmaceuticals
• Enanta Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• LG Chem
• MYR Pharmaceuticals GmbH
• Replicor Inc.
• Roche Holding AG
• Sanofi
• VBI Vaccines Inc.
• Vir Biotechnology, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Hepatitis B Treatment Market to Reach US$5.4 Billion by 2030

The global market for Hepatitis B Treatment estimated at US$4.7 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2024-2030. Acute Type, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Chronic Type segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 4.4% CAGR

The Hepatitis B Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Hepatitis B Treatment Market - Key Trends & Drivers Summarized

Is the Treatment of Hepatitis B Entering a New Era of Functional Cure and Long-Term Suppression?

The treatment of Hepatitis B is undergoing a pivotal transformation, driven by advancing scientific research, improved therapeutic options, and a deeper understanding of the virus's complex life cycle. Traditionally managed through lifelong antiviral therapy, Hepatitis B treatment has focused on suppressing viral replication to reduce the risk of liver cirrhosis, hepatocellular carcinoma (HCC), and liver failure. First-line therapies such as nucleos(t)ide analogues-including entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)-have proven effective in achieving sustained viral suppression, but fall short of offering a complete cure. However, a new wave of research is aiming for what experts call a “functional cure,” defined by the loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA without continued treatment. Novel therapeutic candidates in clinical trials-such as capsid assembly modulators, siRNA inhibitors, and immune checkpoint modulators-are targeting different phases of the HBV life cycle and the host’s immune response to push the boundaries of treatment beyond suppression. Immunotherapeutic strategies including therapeutic vaccines and T-cell activators are also gaining traction, aiming to reawaken the body’s immune response against persistent viral reservoirs. Combination therapies involving antivirals plus immune modulators are being evaluated as a path forward toward sustained off-treatment control. As these investigational therapies progress through clinical trials, the treatment paradigm is shifting from lifelong management to time-limited regimens aimed at achieving functional cure, which would represent a landmark change in the global approach to chronic Hepatitis B.

Is Public Health Infrastructure and Screening Enhancing Treatment Accessibility and Uptake?

As awareness around Hepatitis B grows, improvements in public health infrastructure and global screening efforts are significantly influencing treatment accessibility and uptake. One of the biggest barriers historically has been the lack of diagnosis-most people with chronic HBV remain unaware of their status until complications like liver disease arise. In response, countries are scaling up national screening programs, integrating HBV testing into routine prenatal care, blood donor screening, and general health checkups. These measures are enabling earlier diagnosis, which is crucial since early-stage patients respond more favorably to antiviral therapy. Furthermore, decentralized healthcare models and community-based outreach are being deployed in high-burden regions-especially in Asia and sub-Saharan Africa-to improve access to treatment for underserved populations. Many nations are also revising their treatment guidelines in line with WHO recommendations, reducing the barriers to initiating therapy and expanding eligibility criteria for antiviral treatment. Additionally, integration of HBV management into broader health services such as HIV/AIDS, tuberculosis, and maternal health programs is streamlining care delivery and improving patient outcomes. Global donors and organizations like Gavi, the Global Fund, and UNITAID are supporting low- and middle-income countries by subsidizing medication costs and building lab infrastructure. Meanwhile, digital health platforms and telemedicine services are increasing outreach in remote and rural areas, enabling virtual consultations, remote monitoring, and digital prescription management. Together, these efforts are improving HBV treatment cascade-from diagnosis to retention in care-by making therapy more accessible, affordable, and aligned with the unique needs of diverse patient populations around the world.

How Are Evolving Patient Demographics and Comorbidities Reshaping Treatment Strategies?

Shifting patient demographics, along with an increase in comorbidities such as HIV, hepatitis D, diabetes, and non-alcoholic fatty liver disease (NAFLD), are adding layers of complexity to Hepatitis B treatment strategies. The rise in chronic conditions among aging populations is prompting clinicians to take a more holistic approach when initiating HBV therapy, ensuring that drug choices do not exacerbate renal or bone-related complications. This is especially relevant for older adults or those with underlying kidney disease, where tenofovir alafenamide (TAF) is often preferred over TDF due to its improved safety profile. Co-infection with HIV presents another clinical challenge, as treatment regimens must be harmonized to avoid drug-drug interactions and ensure suppression of both viruses. For patients with hepatitis D virus (HDV) co-infection-a group at higher risk of rapid disease progression-specialized antiviral strategies, including the use of novel entry inhibitors like bulevirtide, are being explored to manage dual infections effectively. In parallel, the global rise of metabolic syndromes and obesity-related liver disorders is influencing treatment timing and monitoring protocols, as liver disease progression in HBV patients is no longer driven solely by viral replication. New algorithms that integrate fibrosis scores, liver enzyme trends, and metabolic indicators are helping providers stratify risk and personalize treatment plans. Furthermore, patient adherence and quality of life considerations are becoming central to therapy design, prompting the development of once-daily oral regimens and the investigation of long-acting injectable formulations. The diversification of HBV patient profiles is thus redefining what personalized medicine looks like in the context of chronic hepatitis care, necessitating more nuanced and patient-centric treatment pathways.

What Market and Policy Drivers Are Accelerating Growth in the Hepatitis B Treatment Segment?

The growth in the Hepatitis B treatment market is driven by several interconnected forces tied to epidemiological trends, pharmaceutical innovation, health policy evolution, and patient behavior. Globally, over 250 million people live with chronic HBV, and the majority reside in low- and middle-income countries-regions now actively scaling up treatment access as part of WHO’s hepatitis elimination agenda. The expansion of treatment guidelines to include patients with earlier-stage liver disease and less advanced fibrosis is widening the eligible treatment population, increasing demand for antiviral therapies. Pharmaceutical innovation continues to drive market momentum, with several next-generation therapies under development aiming to deliver functional cure, improve adherence, or reduce long-term toxicity. Simultaneously, increasing generic drug availability is making first-line antivirals more affordable, especially in high-burden countries, leading to higher patient volumes and expanded public health initiatives. Governments and health agencies are launching hepatitis B elimination plans that include budget allocations for treatment subsidies, centralized procurement strategies, and inclusion of antivirals in essential drug lists-steps that are all contributing to market expansion. Patient behavior is also shifting, with more individuals seeking testing and early intervention due to rising health awareness, digital engagement, and destigmatization of the disease. Meanwhile, partnerships between pharmaceutical companies, NGOs, and health ministries are helping to establish regional treatment hubs and supply chain networks to improve last-mile delivery. The adoption of digital health technologies-such as mobile-based adherence tools, remote monitoring platforms, and AI-powered clinical decision support systems-is enhancing patient retention and care quality. These combined factors are propelling the Hepatitis B treatment market forward, with strong long-term growth anticipated as the world moves closer to eradicating one of the most prevalent infectious diseases.

SCOPE OF STUDY:

The report analyzes the Hepatitis B Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Type, Chronic Type); Treatment (Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment, Surgery Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AbbVie Inc.
• Alnylam Pharmaceuticals
• Altimmune Inc.
• Antios Therapeutics
• Arbutus Biopharma Corporation
• Assembly Biosciences
• Bristol-Myers Squibb
• Dicerna Pharmaceuticals
• Enanta Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• LG Chem
• MYR Pharmaceuticals GmbH
• Replicor Inc.
• Roche Holding AG
• Sanofi
• VBI Vaccines Inc.
• Vir Biotechnology, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Hepatitis B Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • High Global Disease Burden Throws the Spotlight on Expanding Access to Hepatitis B Treatment
  • Increased Government and WHO-Led Elimination Goals Propel Growth in Treatment Uptake
  • Advancements in Antiviral Therapies Strengthen Business Case for Long-Term Viral Suppression
  • Rising Screening and Diagnosis Rates Expand the Addressable Market for Hepatitis B Treatment
  • Development of Finite-Duration Therapies Spurs Innovation in Functional Cure Approaches
  • Growing Pipeline of Novel Nucleos(t)ide Analogs and Immunotherapies Drives R&D Investment
  • Increased Use of Combination Regimens Generates Demand for Optimized Treatment Protocols
  • Improved Access to Generic Medications Sustains Growth in Low- and Middle-Income Countries
  • Integration of Hepatitis B Care into Broader Public Health Programs Expands Treatment Reach
  • Rising Co-Infection Rates with HIV and Hepatitis D Spur Development of Broader-Spectrum Therapeutics
  • Digital Health Tools and Adherence Monitoring Platforms Drive Improved Patient Outcomes
  • Awareness Campaigns and Early Intervention Strategies Propel Patient Engagement and Treatment Initiation
  • Healthcare Infrastructure Improvements in Emerging Markets Strengthen Market Penetration
  • Persistent Stigma and Asymptomatic Nature of Disease Pose Challenges to Treatment Adoption
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Hepatitis B Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acute Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chronic Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immune Modulator Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Antiviral Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Vaccines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• JAPAN
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CHINA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• EUROPE
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Hepatitis B Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• FRANCE
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• GERMANY
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Hepatitis B Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• INDIA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Hepatitis B Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Hepatitis B Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AFRICA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION